Enzolytics Inc (ENZC)

[JohnnyRothrock]

ENZC biotech: why the insane over $7mil-traded-in-3-days?

Answer: a Clinically Stage proven and combined 4 Patents, new HIV and other virus killing biotech has emerged....: and the stock market simply goes crazy over Biotechs more then any other sector.



-What if I told you there was a company that developed a drug for the last 20 years… That has been proven to kill 80% of HIV-1 in patients? How valuable would that be in the biotech world… and just to humanity itself? Well, ENZC is that biotech company:

“Most importantly, viral (HIV) loads in approximately 80% of the blood samples of the patients, after completion of the treatment cycles, came back at non-detectable levels.’

https://www.accesswire.com/453497/Immunotech-Laboratories-Inc-Announces-Successful-Completion-of-Phase-III-Testing-of-the-Patented-Immune-Therapeutic-Vaccine-1



... and also astounding, this new drug was also found to work well with other drugs and on other viruses…with no side effects? How much more valuable would it then be?:

”Other important results noted in the summary report were the positive treatment effect on opportunistic infections, compatibility with all other antiviral drugs, high level of tolerance in all patients and the complete lack of any negative side effects.”

https://www.accesswire.com/453497/Immunotech-Laboratories-Inc-Announces-Successful-Completion-of-Phase-III-Testing-of-the-Patented-Immune-Therapeutic-Vaccine-1



-Most biotechs and new drugs do not make it past preclinical stages and Phase I. Then those that do...most dont make it past Phase II.. But ENZC’s ImmunH did. Under strict European Guidelines ENZC w B-G Europe ImmunH incredibly, already passed Phase I.....and Phase II....:

https://www.businesswire.com/news/home/20140828005129/en/Immunotech-Laboratories-Announces-Successful-Completion-Phase-Phase



and even yes, Phase III clinical trials:

https://www.accesswire.com/453497/Immunotech-Laboratories-Inc-Announces-Successful-Completion-of-Phase-III-Testing-of-the-Patented-Immune-Therapeutic-Vaccine-1



Why is this a big deal? Because of the time and money spent over the years trying to pass a new drug through Trials is a big risk, as most dont make it. Estimated 1 in 5,000 new drugs make it from Preclinical to Phase IV:

“Only 5 in 5,000 drugs that enter preclinical testing progress to human testing. One of these 5 drugs that are tested in people is approved. The chance for a new drug to actually make it to market is thus only 1 in 5,000. Not very good odds.”

https://www.medicinenet.com/script/main/art.asp?articlekey=9877



-And thats why this is a big deal for the new merge with similar biotech HIV and other infection fighting company, BioClonetics. See their website, DD those in the company ...like how the CEO is going to the Davos Forum in January...not only will you find this company also at the cutting edge of infectious diseases - notably HIV with their Clone 3 drug, but that it has the right biotech connections to top Universities, national labs and even being asked this year by NIH to partipate in finding a vaccine for Covid with other top biotech companies; BioClonetics is an up and coming biotech player. From BioClonetics website....which you will see is the perfect fit for ENZC:


“These tests demonstrate that the Clone 3 active vaccine component prevented progression to AIDS-like illness, and also supports the conclusion that the peptide of the Clone 3 epitope (KLIC) will be effective as an active vaccine against HIV/AIDS.
  
 Additional evidence allows the company to project that its antibody will neutralize over 98% of the HIV viral strains (clades) worldwide based upon information confirmed by the U.S. Government?s National Laboratory HIV clinical isolate database at Los Alamos, NM. Specifically, to date, Los Alamos has currently reported 4,556 clinical HIV-1 variants or subtypes (February 2015). The company has determined that the site on the virus to which Clone 3 binds in the neutralization step (its epitope) is highly conserved in 98% of the HIV-1 viral strains. Based on this knowledge and other independent in vivo clinical-correlate evidence from five (5) additional independent research institutions, the company's proprietary antibody is expected to provide a safe immunotherapeutic long-term remission for people living with HIV/AIDS and an effective active vaccine that protects uninfected individuals from HIV infection.”

http://bioclonetics.com/validation.html


In closing, combining BioClonetics with ENZC thus creates an HIV worldwide (based in Texas and Easter Europe) powerhouse. Because you have ENZC’s Clinical Stage proven 80% kill rate of HIV (that via merge BioClonetics gets 20 years and millions of dollars spent of successful Trials for free: no less them a revolutionary Phase IV new HIV killing drug)....and the stock price is subpenny, lol.

- - Anyone out there can look up Naz or OTC biotechs who have not passed Phase III with their lead drug, yet their market caps are in the tens of millions to hundreds of millions - ALL BASED ON PURE SPECULATION...as again, most dont pass Phase III - but does it hurt the stock price? No. Of countless examples, i like to use IHub’s Most Read stock......NWBO ....with its almost $700 million market cap, and pages of Warrants and convertibles. 760 million OS. In Phase III.

ENZC? $12 million market cap. 2 billion OS. Passed Phase III. ...and now merging with BioClonetics. But NWBO has about a 7,000% higher market cap(!). So as time goes on here and things come together like closing of the deal and updated filings, even at a dime, the market cap for ENZC would be only $200 million, still 500% less, yet a world leader and innovator for new HIV drugs, one of which already passed all its Trials with flying colors and no side effects.

ENZC: mini biotech unicorn monster in the making, by all accounts...